The Age: ‘The moment you walk in through those doors your healing starts’: Victoria leading the race on Indigenous vaccination
Data released by the federal government has highlighted the widening gap between fully vaccinated Indigenous Australians and the overall population, and the direct impact COVID-19 will have on First Nations people if Australia eases restrictions once 70 or 80 per cent of adults are vaccinated.
Historically, Australia’s Aboriginal community has been heavily impacted by the effects of widespread viral infections such as measles, smallpox and the Spanish Flu and this article highlights the impact low COVID-19 vaccination rates could have on our First Nations people.
Despite the slow rollout, Victoria is leading the way in terms of vaccination rates amongst the Indigenous population with 43% of people fully vaccinated against COVID-19, more than double that of the non-Indigenous population in Victoria at 26%.
According to Jeroen Weimar, the COVID-19 response commander in Victoria, the states’ success with facilitating a competent roll out initiative amongst the Indigenous communities can be attributed to joint efforts and strong partnerships.
लेख को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें।
The Age: ‘The moment you walk in through those doors your healing starts’: Victoria leading the race on Indigenous vaccination
WHO: Safety profile of nOPV2 vaccine
In an attempt to implement a global eradication initiative of the polio virus, the first type 2 novel oral polio vaccine (nOPV2) became the first vaccine to be authorised for use under the WHO Emergency Use Listing (EUL) apparatus. However, the current nOPV2 vaccine presents an increased risk of type 2 circulating vaccine-derived polioviruses (cVDPV2), especially in communities with low immunization rates. African countries continue to be amongst the most impacted by this potentially lethal virus. Consequentially, the use of the nOPV2 is currently restricted and SAGE recommended that an independent safety monitoring group be established (GACVS) and maintain thorough safety observations during the entire period of the EUL.
Under the current EUL, there is a 2 phase roll out of the nOPV2 vaccine. With phase 1, countries must first meet stringent initial use criteria and verification requirements including continuous flaccid paralysis (AFP) monitoring to attain approval for use. Following this, phase 2 supports the use of the nOPV2 vaccine as a standard response for cVDPV2 outbreaks.
Following rigorous safety criteria, as of 9 June 2021, 7 countries have received approval for use authorisation of the nOPV2 vaccine and 25 countries are still pending. Majority of the nOPV2 doses thus far have been administered in Nigeria (17 899 130) and Liberia (853 279) amongst children 5 years of age and under in the form of two oral vaccine drops. GACVS is working closely with the Liberian and Nigerian governments to implement AESI surveillance and ongoing AFP data to ensure the safety and effectiveness of the vaccine in preventing polio infection. Current preliminary data analysis did not indicate elevated safety issues associated with the nOPV2 vaccine, however GACVS members have stressed that prolonged, comprehensive surveillance is imperative to signal imminent safety concerns.
To read the extract in full, please click on the link below:
WHO: Safety profile of nOPV2 vaccine
एबीसी न्यूज यूएस: अधिकारी का कहना है कि एफडीए द्वारा अनुमोदित फाइजर वैक्सीन बच्चों में ऑफ-लेबल उपयोग के लिए ठीक नहीं है
अमेरिकी खाद्य एवं औषधि प्रशासन (एफडीए) ने 16 वर्ष से अधिक उम्र के लोगों के लिए फाइजर कोविड-19 वैक्सीन की पूर्ण मंजूरी के बाद सलाह जारी की है कि इसे छोटे बच्चों को ऑफ-लेबल उपयोग के रूप में नहीं दिया जाना चाहिए।
Pfizer's COVID-19 vaccine was 12 से 15 वर्ष की आयु के बच्चों में उपयोग के लिए अधिकृत मई में एफडीए द्वारा, ईयूए में संशोधन के सभी मानदंडों को पूरा करते हुए और 12-15 आयु वर्ग के बच्चों में 1001टीपी3टी प्रभावशीलता के साथ। इसके अतिरिक्त, मॉडर्ना और जॉनसन एंड जॉनसन दोनों टीके अमेरिका में 18 वर्ष और उससे अधिक उम्र के किसी भी व्यक्ति के लिए उपलब्ध हैं, मॉडर्ना अभी भी एफडीए के साथ आपातकालीन उपयोग प्राधिकरण पर अनुमोदन के निर्णय का इंतजार कर रही है।
5-11 साल के बच्चों पर फाइजर वैक्सीन सुरक्षा डेटा सितंबर के अंत तक प्रस्तुत किया जाना है, मॉडर्ना की रिपोर्ट गिरावट के बीच में आने वाली है। क्लिनिकल परीक्षण अभी भी चल रहे हैं, हालांकि, यह उम्मीद की जाती है कि 5-11 वर्ष की आयु के बच्चों के लिए पहला टीका 2021 के अंत तक या 2022 की शुरुआत में हो सकता है। रोल आउट शुरू होने से पहले दुर्लभतम दुष्प्रभावों का पता लगाने के लिए अमेरिका, एफडीए ने सलाह दी है कि परीक्षणों के लिए स्वयंसेवकों के पूल का विस्तार करने की आवश्यकता होगी।
लेख को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें
एबीसी न्यूज यूएस: अधिकारी का कहना है कि एफडीए द्वारा अनुमोदित फाइजर वैक्सीन बच्चों में ऑफ-लेबल उपयोग के लिए ठीक नहीं है
Federal Government Announces No Fault COVID-19 Indemnity Scheme
Federal Health Minister Greg Hunt has announced the details of the no fault COVID-19 Vaccine Claim Scheme following extensive consultation with the peak medical, healthcare, business and insurance sectors to ensure a comprehensive National Scheme.
The purpose of the Scheme will be to provide Australians with quick access to compensation for COVID-19 claims related to the administration of a Therapeutic Goods Administration approved COVID-19 vaccine delivered through a Commonwealth Government approved program.
From 6 September Australians who suffer injury and loss of income due to their COVID-19 vaccine will be able to register their intent to claim from the COVID-19 vaccine claims scheme webpage.
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
Federal Government Announcement: No Fault COVID-19 Indemnity Scheme
ATAGI recommendations on the use of COVID-19 vaccines in all young adolescents in Australia
The Australian Technical Advisory Group on Immunisation (ATAGI) has released recommendations on the use of COVID-19 vaccines in all young adolescents in Australia.
The advice recommends children aged 12-15 be vaccinated against COVID-19 using Comirnaty (Pfizer).
A summary of ATAGI recommendations includes:
- Vaccination against COVID-19 is recommended for all individuals from 12 years of age, extending the current recommendation for those aged 16 years and older.
- A two-dose schedule using Comirnaty (Pfizer), the only vaccine currently registered for use in Australia in this age group, is recommended.
- Recommendations on the use of Spikevax (Moderna) for adolescents will be finalised following the decision on provisional registration of Spikevax (Moderna) in this age group.
To read the statement in full, please click the link below:
ATAGI recommendations on the use of COVID-19 vaccines in all young adolescents in Australia
MCRI's Professor Fiona Russell joins ABC Q+A host, Virgina Trioli tonight at 8:30pm AEST
MCRI's Professor Fiona Russell joins ABC Q+A host, Virginia Trioli, tonight at 8:30pm AEST for an important discussion around the COVID-19 Delta variant, lockdowns and their impact on children, teens and young people.
For more details, please click on the link below:
ABC Q+A
Independent: 'A potential first step forward’: Moderna to launch human trials for new HIV vaccines
A positive development in the immunisation space as American biotech company, Moderna is prepared to commence human trials for their new HIV vaccines.
The company will apply the same mRNA technology they successfully used against the COVID-19 virus, hoping to break new grounds fighting another deadly disease. This turning point has been described as a “potential first step forward” in protecting people from becoming infected with HIV. However, due to the elevated complexity of the HIV virus, scientists warn there is still a long way to go before mRNA technology can be used to provide long-lasting protection.
The aim of the Moderna mRNA vaccines is to prompt an immune response by introducing broadly neutralising antibodies. It is believed that multiple vaccines will be required to overcome key challenges and generate a sufficient response. Moderna is set to recruit 56 healthy people between the ages of 18 to 50 years of age to participate in their phase 1 trial which is anticipated to run until May 2023.
लेख को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें:
Independent: 'A potential first step forward’: Moderna to launch human trials for new HIV vaccines
People aged 16 - 39 in a priority group now eligible for the Pfizer vaccine
The Australian Government has expanded the vaccine eligibility criteria to allow people aged 16-39 in a priority group to receive the Pfizer vaccine.
To learn more about eligibility for 16 to 39 year-olds in the COVID-19 vaccination program, please click on the link below.
The Australian Government COVID-19 vaccination program for 16 to 39 year olds.
The Medical Journal of Australia podcast: COVID-19 in children
MVEC's Associate Professor Nigel Crawford and Dr Laila Ibrahim, paediatrician and researcher at the Royal Children's Hospital feature on the latest edition of the Medical Journal of Australia podcast.
In this podcast, Nigel and Laila discuss COVID-19 in children, to accompany their co-authored research focused on examining the epidemiological and clinical characteristics of SARS‐CoV‐2‐positive children in Australia during 2020.
You can listen to the podcast here:
MJA Podcast: Episode 33: COVID-19 in children, with Dr Laila Ibrahim and Dr Nigel Crawford
पंजीकरण अब अगस्त सीवीयू मिनी कार्यक्रम के लिए खुला है
The next Clinical Vaccinology Update (CVU) miniseries event, दिल के मामले: COVID-19 mRNA टीकाकरण से जुड़े मायोकार्डिटिस और पेरिकार्डिटिस, will be held virtually on Monday 30th August 2021.
We are excited to welcome our panel who will take an in-depth look at an important vaccine safety signal associated with COVID-19 mRNA vaccines (Pfizer and Moderna), myocarditis and pericarditis. The session will also include a live Q&A panel with experts from the medical, consumer (Heart Foundation) and vaccine safety domains.
Further details can be found via our Events page and the link below: